Immutep Limited Adr stock is traded at $3.25, with a volume of 76,302. It is down -0.31% in the last 24 hours and up +1.56% over the past month. Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Previous Close:
$3.26
Open:
$3.16
24h Volume:
76,302
Relative Volume:
1.51
Market Cap:
$23.95M
Revenue:
$2.67M
Net Income/Loss:
-$54.17M
P/E Ratio:
-
EPS:
-$0.3699
Net Cash Flow:
-$39.34M
1W Performance:
-8.71%
1M Performance:
+1.56%
6M Performance:
-67.11%
1Y Performance:
-90.71%
1-Day Range:
$3.06$3.50
1-Week Range:
$3.06$3.76
52-Week Range:
$2.66$70.60
Immutep Limited Adr Stock (IMMP) Company Profile
Market Cap
Revenue
Net Income
Cash Flow
EPS